Hyperthermia Safety Study Uses Temperature Management System to Gently Raise Participant's Body Temperature to a Fever-range Level in a Controlled Setting. (BTT)

April 29, 2026 updated by: Marc Abreu

Clinical and Biological Safety Study of the BTT Hyperthermia in Adult Subjects

The Abreu BTT 700 Temperature Management System (TMS) is a device that gently raises the body temperature of the participant to a fever-range level in a controlled setting. There will be one study treatment session. with the TMS system and four safety assessments: before the session, about two hours afterward, on the next day, and again on the third day after the session. Your participation in the study will last about three days in total. An electrocardiogram (ECG - traces the electrical activity of the heart) will be performed during screening. This is not a randomized or blinded study -- all participants will receive the same study treatment. The TMS system has been previously used in other settings, but this study is designed specifically to collect safety data in adult volunteers.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Participants are being asked to take part because they are healthy adults between the ages of 18 and 65 and have no history of any heart, cancer, or neurological disorders. Participation in this study will help researchers understand how healthy people respond to this technology before it is tested in people with specific medical conditions.

Voluntary Participation: Taking part in this study is completely voluntary. Volunteers do not have to participate and may withdraw at any time. Stopping to participate in the study will not result in any penalties or loss of benefits.

Benefits, Compensation, and Risk: Subjects may not receive any direct benefit from participating in this study. However, participation will help researchers develop safer treatments for others in the future. There is no cost to participate.

Possible risks include feeling tired, sweating, or experiencing temporary changes in heart rate or blood pressure. Rare but serious risks could include overheating, dehydration, or fainting. The study team will monitor you closely throughout the process to minimize risks and will stop the session immediately if there are any safety concerns.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Aventura, Florida, United States, 33160
        • BTT Medical Institute LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

- A person who meets all of the following criteria will be eligible for this study:

  • Provision of signed and dated informed consent/assent form.

    • Ability to understand the nature of the study and protocol requirements and provide written informed consent.
  • Willingness to comply with all study procedures and availability for the duration of the study.
  • Aged over 18 years and no more than 65 years
  • Males and Female

  • Values of vital signs before BTT Hyperthermic Induction should be:

    • Systolic between 100-140 mm Hg o diastolic between 50-90 mm Hg
    • cardiac pulse between 45-90 beats per minute
  • Free from any treatment in the 7 days preceding inclusion including no use of analgesics or anti-inflammatory drugs)

Exclusion Criteria:

  • History of Cardiovascular and venous thrombosis disorders

    • History of auto-immune disorders
    • History of pulmonary disease
    • History of Neurological disorders
    • History of Cancer disorders
    • Renal or Hepatic insufficiency
    • Medical history and / or surgical judged by the investigator or his representative as being incompatible with the test, especially subjects who do not support high fever range in the past during adult or childhood life.
    • Pathology evolutionary time of the review of inclusion
    • Excessive consumption of alcohol, tobacco (over 10 cigarettes / day), coffee, tea or drinks containing caffeine (equivalent to more than 4 cups per day) or drug abuse.

    • The person(s) with the following condition(s) are excluded to participate in the study

      1. Implanted electronic devices
      2. Any metal implant
      3. Dermatological conditions sensitive to heat
      4. Any enclosed infection that, as assessed by a qualified physician, serves as a contraindication for hyperthermia
      5. Clinically significant ECG findings, as per determined by a cardiologist, including uncontrolled arrhythmia
      6. A subject who in the opinion of the Principal Investigator would not be able to safely complete the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single Arm with one hyperthermia treatment
one hyperthermia treatment
Other: Hyperthermia
controlled induced hyperthermia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline (pre-treatment) through post-treatment (48-hours post treatment)

Incidence, type, and severity of treatment-emergent adverse events following whole-body hyperthermia (WBH).

  • Unit of Measure: Number and percentage of participants (%)
  • Measurement Tool: AE/SAE reporting using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and MedDRA coding
Baseline (pre-treatment) through post-treatment (48-hours post treatment)
Change in Cardiovascular Vital Signs (Heart Rate)
Time Frame: Baseline (pre-treatment) through post-treatment (48-hours post treatment)
  • Change from baseline in heart rate.

  • Parameters:

    • Heart rate (beats per minute)
  • Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Automated vital signs monitor
Baseline (pre-treatment) through post-treatment (48-hours post treatment)
Change in Cardiovascular Vital Signs (Blood Pressure)
Time Frame: Baseline (pre-treatment) through post-treatment (48-hours post treatment)]

Change from baseline in blood pressure.

Parameters:

Systolic/diastolic blood pressure (mmHg) Unit of Measure: Absolute values and change from baseline Measurement Tool: Automated vital signs monitor
Baseline (pre-treatment) through post-treatment (48-hours post treatment)]
Change in Comprehensive Metabolic Panel Renal Function Markers (Creatinine)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
  • Change from baseline in renal function markers Creatinine

  • Parameters:

    • Renal: Creatinine (mg/dL)
  • Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Comprehensive Metabolic Panel Renal Function (BUN)
Time Frame: Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)
  • Change from baseline in renal function markers BUN

  • Parameters:

    • BUN (mg/dL)
  • Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)
Change in Comprehensive Metabolic Panel Renal Function (eGFR)
Time Frame: Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)

Change from baseline in renal function markers. (eGFR)

  • Parameters: eGFR (mL/min/1.73m²) Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)
Change in Comprehensive Metabolic Panel Hepatic Function (AST)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Change from baseline in Hepatic function markers. (AST)

  • Parameters: AST (U/L) Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Comprehensive Metabolic Panel Hepatic Function (ALT)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Change from baseline in Hepatic function markers. (ALT)

  • Parameters: AST (U/L) Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Comprehensive Metabolic Panel Hepatic Function (ALP)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Change from baseline in Hepatic function markers. (ALP)

  • Parameters: ALP (U/L) Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Comprehensive Metabolic Panel Hepatic Function (Total Bilirubin)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Change from baseline in Hepatic function markers. (Total Bilirubin)

  • Parameters: Total Bilirubin (mg/dL) Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Comprehensive Metabolic Panel Hepatic Function (GGT)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Change from baseline in Hepatic function markers. (GGT)

• Parameters: GGT (U/L) Unit of Measure: Absolute values and change from baseline • Measurement Tool: Clinical chemistry analyzer (Comprehensive Metabolic Panel)
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Hematologic Parameters (CBC- White Blood Cell Count)
Time Frame: Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)
  • Change from baseline in hematologic indices.
  • Parameters: White Blood Cell Count
  • Unit of Measure: Standard laboratory units (thousand cells/µL)
  • Measurement Tool: Automated hematology analyzer
Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)
Change in Hematologic Parameters (CBC- Hemoglobin)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Change in Hematologic Parameters (CBC- Hemoglobin) Change from baseline in hematologic indices.

  • Parameters: Hemoglobin
  • Unit of Measure: Standard laboratory units (g/dL)
  • Measurement Tool: Automated hematology analyzer
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Hematologic Parameters (CBC- Hematocrit)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Change from baseline in hematologic indices.

  • Parameters: Hematocrit
  • Unit of Measure: Standard laboratory units (%)
  • Measurement Tool: Automated hematology analyzer
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Hematologic Parameters (CBC- Platelet Count)
Time Frame: Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)

Change from baseline in hematologic indices.

  • Parameters: Platelet count
  • Unit of Measure: Standard laboratory units (thousand/uL )
  • Measurement Tool: Automated hematology analyzer
Baseline (pre-treatment), post-treatment ( 24hrs. and 48-hours post treatment)
Change in Hematologic Parameters (CBC- Erythrocyte Sedimentation Rate)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
  • Change from baseline in hematologic indices.
  • Parameters: Erythrocyte Sedimentation Rate (ESR)
  • Unit of Measure: Standard laboratory units (mm/hr) • Measurement Tool: Automated hematology analyzer
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
Change in Hematologic Parameters (C-Reactive Protein)
Time Frame: Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)
  • Change from baseline in hematologic indices.
  • Parameters: C-Reactive Protein (CRP)
  • Unit of Measure: Standard laboratory units (mg/L)
  • Measurement Tool: Automated hematology analyzer
Baseline (pre-treatment), post-treatment (24hrs. and 48-hours post treatment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Respiratory Parameters (Respiratory Rate)
Time Frame: Pretreatment through 48hrs. after the treatment
  • Change from baseline in respiratory rate

  • Parameters:

    • Respiratory rate (breaths/min)
  • Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Pulse oximeter and respiratory monitor
Pretreatment through 48hrs. after the treatment
Change in Respiratory Parameters (Oxygen Saturation)
Time Frame: Pretreatment through 48hrs. after the treatment

Change from baseline in oxygen Saturation.

  • Parameters: Oxygen saturation (%)
  • Unit of Measure: Absolute values and change from baseline
  • Measurement Tool: Pulse oximeter and respiratory monitor
Pretreatment through 48hrs. after the treatment
Change in Pulmonary Function (FEV1)
Time Frame: Pretreatment and 48hrs. after the treatment
  • Description: Change from baseline in pulmonary performance.
  • Unit of Measure: Standard spirometry parameters FEV1 (liters)
  • Measurement Tool: Spirometer
Pretreatment and 48hrs. after the treatment
Change in Pulmonary Function (FVC)
Time Frame: Pretreatment and 48hrs. after the treatment
Change from baseline in pulmonary performance. Unit of Measure: Standard spirometry parameters FVC (liters) Measurement Tool: Spirometer
Pretreatment and 48hrs. after the treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Marc Abreu

Investigators

  • Principal Investigator: Marcio Abreu, MD, BTT Medical Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

April 17, 2026

First Submitted That Met QC Criteria

April 29, 2026

First Posted (Actual)

May 4, 2026

Study Record Updates

Last Update Posted (Actual)

May 4, 2026

Last Update Submitted That Met QC Criteria

April 29, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BTT 25-001 SS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Safety Study

Clinical Trials on Hyperthermia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe